BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced it has commenced a process to explore and evaluate strategic options to enhance and preserve shareholder value.

Altus Power, Inc. (“Altus Power”) (NYSE: AMPS), the premier independent owner and operator of commercial-scale solar facilities, today announced that it will release financial results for the second quarter of 2022 before the market opens on Monday, August 15, 2022.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open.

Eisai Co. Ltd (Headquarters: Toyoko, CEO: Haruo Naito, “Eisai”) announced today that the company will present research from its Alzheimer’s disease (AD) pipeline, including new data for lecanemab (BAN2401).

Forecast to 2030,’ thoroughly examines the Hidradenitis Suppurativa industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Lactose Intolerance industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Leupeptin industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Osteomyelitis Treatment industry to provide essential data & information for the targeted readers.

Forecast to 2030,’ thoroughly examines the Postpartum Depression industry to provide essential data & information for the targeted readers.